Back to Search
Start Over
Crizotinib resistance: BRAF mutation implications for therapeutic strategies.
- Source :
-
Cancer treatment and research communications [Cancer Treat Res Commun] 2021; Vol. 28, pp. 100391. Date of Electronic Publication: 2021 May 13. - Publication Year :
- 2021
-
Abstract
- Drug-resistant mutations constitute a significant cause of crizotinib treatment failure for non-small cell lung cancer, which poses a major clinical challenge in the successful treatment of non-small cell lung cancer; therefore, the discovery of the resistance mechanisms of crizotinib is of utmost importance. Understanding the acquired BRAF 600E mutation is essential for designing new effective therapeutic combinations against disease progression.<br /> (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Subjects :
- Carcinoma, Non-Small-Cell Lung genetics
Humans
Lung Neoplasms genetics
Mutation
Proto-Oncogene Proteins B-raf antagonists & inhibitors
Antineoplastic Agents therapeutic use
Carcinoma, Non-Small-Cell Lung drug therapy
Crizotinib therapeutic use
Drug Resistance, Neoplasm
Lung Neoplasms drug therapy
Protein Kinase Inhibitors therapeutic use
Proto-Oncogene Proteins B-raf genetics
Subjects
Details
- Language :
- English
- ISSN :
- 2468-2942
- Volume :
- 28
- Database :
- MEDLINE
- Journal :
- Cancer treatment and research communications
- Publication Type :
- Academic Journal
- Accession number :
- 34004505
- Full Text :
- https://doi.org/10.1016/j.ctarc.2021.100391